MedTrace Logo

HRS-AKI Treatment With TIPS in Patients With Cirrhosis

NCT05346393 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2024-11-18

No results posted yet for this study

Summary

The study compares the effectiveness and safety of TIPS implantation in patients with HRS-AKI (stage1, 2 and 3) and liver cirrhosis with standard therapy (drug therapy with terlipressin + albumin).

Conditions

Interventions

PROCEDURE

TIPS

A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver

DRUG

Standard of Care

Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • University Hospital Halle (Saale)

    collaborator UNKNOWN

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Cristina Ripoll, Prof. Dr. · Jena University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2025-06-30
Completion
2026-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346393 on ClinicalTrials.gov